News | May 27, 2014

MRI Adaptive Radiation Therapy: Patients Spared Additional Radiation

May 27, 2014 — ECRI Institute released a Health Technology Forecast regarding the use of integrated magnetic resonance imaging (MRI) to better target radiation therapy. Use of image-guided radiation therapy (IGRT) and treatment planning technology is gaining interest among clinicians who wish to increase the accuracy and precision of radiation therapy (RT). Systems that integrate a MRI scanner and RT gantry are considered a novel approach to IGRT, allowing clinicians to use both functions concurrently to guide RT with real-time images. Clinicians can reportedly use accompanying software to speed calculations for real-time adjustments to dosing, contouring and timing. Patients with tumors likely to move, or tumors located in close proximity to organs likely to move, during treatment are the most likely candidates for real-time MRI adaptive radiation therapy (ART). Use of real-time MRI ART will likely be limited until data are published that support the approach’s superior efficacy and improved patient outcomes compared with other IGRT options.

Available alternative technologies can offer near real-time or repeated interfraction ART guidance using other imaging technology; therefore, competition with these similar methodologies will likely limit use of real-time MRI ART. However, some patients and clinicians might prefer MRI guidance because it purportedly provides better soft-tissue contrast and does not expose patients to additional radiation compared with computed tomography (CT)-based image guidance.

The ViewRay system (ViewRay Inc.), which combines MRI with cobalt-60 (60Co) RT, was cleared for marketing by the U.S. Food and Drug Administration (FDA) in May 2012. As of December 2013, three facilities had installed ViewRay systems and were conducting internal studies on the efficacy of real-time MRI ART; however, none of the facilities had yet been approved by the U.S. Nuclear Regulatory Commission (NRC) to use the ViewRay for clinical applications. FDA did not require ViewRay to conduct clinical trials before marketing clearance, so limited data are available to assess its safety and efficacy. Adoption would likely increase if facilities conducting internal studies can show increased efficacy for the ViewRay system compared with other available image-guidance systems (i.e., CT-based technologies). Other real-time MRI ART systems are still in development; these are unlikely to be commercially available for clinical use before 2017.

Published data indicating that real-time MRI ART improves patient outcomes compared with available IGRT technologies are lacking. It is unclear whether movement of tumors or organs during treatment is significant enough to require real-time MRI ART, or if this approach is an improvement over other IGRT technology. Real-time MRI ART might improve health outcomes if it is proven to increase targeting accuracy, decrease radiation exposure of surrounding healthy tissues, or allows clinicians to escalate radiation doses due to increased confidence.

The ViewRay system costs about $8.5 million, with vault construction to house the system potentially costing an additional $1.5 million. If demand for this therapy increases, treatment centers could potentially recoup acquisition costs since patients receiving IGRT represent a large potential patient pool. However, as of December 2013, no ViewRay systems have been approved by NRC for clinical use and treatment pricing has not been established.

Reimbursement for real-time MRI ART from the U.S. Centers for Medicare & Medicaid Services (CMS) and private payers is not available.

For more information:

Related Content

Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.


News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Philips Receives FDA 510(k) for Ingenia Elition MR System
Technology | Magnetic Resonance Imaging (MRI) | June 07, 2018
Philips announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
Overlay Init